CRX 103Alternative Names: CRX-103
Latest Information Update: 15 Aug 2007
At a glance
- Originator GlaxoSmithKline
- Class Antineoplastics
- Mechanism of Action DNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 12 Jul 2005 Corixa Corporation has been acquired and merged into GlaxoSmithKline
- 13 Nov 2001 New profile
- 13 Nov 2001 Preclinical development for Cancer in USA (IV)